KNect365 Life Sciences is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Next Generation Therapeutics

Antibody Engineering and Therapeutics Survey: Emerging technologies and novel approaches - have your say

Antibodies therapeutics survey on emerging technologies

Emerging technologies such as AI, next generation sequencing and display systems are changing the way antibodies are being engineered at a rapid rate. At the same time, novel approaches to identifying targets and delivering antibodies are improving therapeutic effectiveness. However, there are still plenty of challenges that need to be overcome.


The Antibody Engineering & Therapeutics conference series is conducting a survey of industry professionals from pharma, biotechs, academia, CDMOs, service providers and regulators around the world. The final report will reveal unique insights into the hottest potential opportunities and the biggest challenges around emerging technologies and novel approaches in antibody engineering and therapeutics.

Click here to take part in the survey.


Complete the survey to win a free conference pass

Completing the survey will take just 5 minutes and will give you exclusive early access to the final report. All answers will remain anonymous. Plus, everyone who completes the survey by Sunday 18th August 2019 will be entered into a prize draw for a free conference pass to their choice of KNect365 Antibody Engineering & Therapeutics conferences (full terms and conditions can be found here):

- 4 day pass: Antibody Engineering & Therapeutics - 9-13 December 2019, San Diego, CA
- 3 day pass: Antibody Engineering & Therapeutics Asia - 24-26 February 2020, Kyoto, Japan
- 2 day pass: Antibody Engineering & Therapeutics Europe – 10-11 June 2020, Amsterdam, The Netherlands

We’re excited to see the results of this study and we hope you are too.

Click here to take part in the survey.